Historical Valuation
Lucid Diagnostics Inc (LUCD) is now in the Overvalued zone, suggesting that its current forward PS ratio of 19.02 is considered Overvalued compared with the five-year average of -2.09. The fair price of Lucid Diagnostics Inc (LUCD) is between 0.63 to 1.03 according to relative valuation methord. Compared to the current price of 1.18 USD , Lucid Diagnostics Inc is Overvalued By 14.57%.
Relative Value
Fair Zone
0.63-1.03
Current Price：1.18
14.57%
Overvalued
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Lucid Diagnostics Inc (LUCD) has a current Price-to-Book (P/B) ratio of -4.90. Compared to its 3-year average P/B ratio of 2.48 , the current P/B ratio is approximately -297.27% higher. Relative to its 5-year average P/B ratio of 2.05, the current P/B ratio is about -338.86% higher. Lucid Diagnostics Inc (LUCD) has a Forward Free Cash Flow (FCF) yield of approximately -28.65%. Compared to its 3-year average FCF yield of -59.08%, the current FCF yield is approximately -51.51% lower. Relative to its 5-year average FCF yield of -49.80% , the current FCF yield is about -42.46% lower.
P/B
Median3y
2.48
Median5y
2.05
FCF Yield
Median3y
-59.08
Median5y
-49.80
Competitors Valuation Multiple
AI Analysis for LUCD
The average P/S ratio for LUCD competitors is 4.23, providing a benchmark for relative valuation. Lucid Diagnostics Inc Corp (LUCD.O) exhibits a P/S ratio of 19.02, which is 349.81% above the industry average. Given its robust revenue growth of 3.33%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for LUCD
1Y
3Y
5Y
Market capitalization of LUCD increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of LUCD in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is LUCD currently overvalued or undervalued?
Lucid Diagnostics Inc (LUCD) is now in the Overvalued zone, suggesting that its current forward PS ratio of 19.02 is considered Overvalued compared with the five-year average of -2.09. The fair price of Lucid Diagnostics Inc (LUCD) is between 0.63 to 1.03 according to relative valuation methord. Compared to the current price of 1.18 USD , Lucid Diagnostics Inc is Overvalued By 14.57% .
What is Lucid Diagnostics Inc (LUCD) fair value?
LUCD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Lucid Diagnostics Inc (LUCD) is between 0.63 to 1.03 according to relative valuation methord.
How does LUCD's valuation metrics compare to the industry average?
The average P/S ratio for LUCD's competitors is 4.23, providing a benchmark for relative valuation. Lucid Diagnostics Inc Corp (LUCD) exhibits a P/S ratio of 19.02, which is 349.81% above the industry average. Given its robust revenue growth of 3.33%, this premium appears unsustainable.
What is the current P/B ratio for Lucid Diagnostics Inc (LUCD) as of Jan 10 2026?
As of Jan 10 2026, Lucid Diagnostics Inc (LUCD) has a P/B ratio of -4.90. This indicates that the market values LUCD at -4.90 times its book value.
What is the current FCF Yield for Lucid Diagnostics Inc (LUCD) as of Jan 10 2026?
As of Jan 10 2026, Lucid Diagnostics Inc (LUCD) has a FCF Yield of -28.65%. This means that for every dollar of Lucid Diagnostics Inc’s market capitalization, the company generates -28.65 cents in free cash flow.
What is the current Forward P/E ratio for Lucid Diagnostics Inc (LUCD) as of Jan 10 2026?
As of Jan 10 2026, Lucid Diagnostics Inc (LUCD) has a Forward P/E ratio of -3.09. This means the market is willing to pay $-3.09 for every dollar of Lucid Diagnostics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Lucid Diagnostics Inc (LUCD) as of Jan 10 2026?
As of Jan 10 2026, Lucid Diagnostics Inc (LUCD) has a Forward P/S ratio of 19.02. This means the market is valuing LUCD at $19.02 for every dollar of expected revenue over the next 12 months.